OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis

Oncoimmunology
Patrizia NanniPier-Luigi Lollini

Abstract

This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called "Triplex". Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocompatibility antigens) and was previously found able to prevent autochthonous HER2/neu-driven mammary carcinogenesis. Timing of aOX40 administration, concomitantly or after cell vaccination, gave opposite results. Unexpectedly, vaccine efficacy was hampered by concomitant OX40 triggering. Such decreased immunoprevention was likely due to a reduced induction of anti-HER2/neu antibodies and to a higher level of Treg activation. On the contrary, aOX40 administration after the completion of vaccination slightly but significantly increased immunopreventive vaccine efficacy, and led to increased production of GM-CSF and IL10. In conclusion, OX40 triggering can either impair or ameliorate immunoprevention of HER2/neu-driven mammary carcinogenesis depending on the schedule of aOX40 administration.

References

Aug 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Patrizia NanniPier-Luigi Lollini
Jan 6, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Satoshi MurataR Todd Reilly
Feb 25, 2006·Nature Reviews. Cancer·Pier-Luigi LolliniGuido Forni
Jul 20, 2007·Cancer Research·Jennifer B JacobWei-Zen Wei
Oct 25, 2007·Nature Reviews. Cancer·Mario P Colombo, Silvia Piconese
Mar 26, 2008·The Journal of Experimental Medicine·Silvia PiconeseMario P Colombo
Jul 3, 2008·Cancer Research·Michael J GoughAndrew D Weinberg
Jul 3, 2008·Cancer Research·Ana Lucia Dominguez, Joseph Lustgarten
Jan 22, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carl E Ruby, Andrew D Weinberg
May 21, 2009·International Journal of Cancer. Journal International Du Cancer·Naomi KitamuraTohru Tani
Oct 7, 2010·Cancer Research·Arianna PalladiniPier-Luigi Lollini
Nov 22, 2012·Oncoimmunology·Vivian L WeissTodd D Armstrong
Jan 15, 2014·Current Opinion in Immunology·Hiroyoshi Nishikawa, Shimon Sakaguchi
Apr 16, 2014·Immunology and Cell Biology·Yannick BulliardJennifer L Brogdon
Apr 30, 2014·Cancer Immunology Research·Martin Oft
Mar 13, 2015·Frontiers in Oncology·Stefanie N LinchWilliam L Redmond
Dec 10, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sandrine AspeslaghAurélien Marabelle
Jan 6, 2016·Proceedings of the National Academy of Sciences of the United States of America·Stefanie N LinchWilliam L Redmond
Jan 23, 2016·Current Opinion in Immunology·Olivera J Finn, Pamela L Beatty
Nov 9, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stéphane ChampiatCharles Ferté
Nov 10, 2016·Vaccines·Soumaya KarakiEric Tartour
Sep 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J MessenheimerBernard A Fox
Feb 2, 2018·Science Translational Medicine·Idit Sagiv-BarfiRonald Levy

❮ Previous
Next ❯

Citations

Sep 17, 2021·Journal of Cancer Research and Therapeutics·Ruby DharSubhradip Karmakar

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
ELISA

Software Mentioned

FlowJo
Treestar

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.